Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02791230 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,733
- Enrollment target
NCT02791230: Completed Phase 3 study, sponsored by Pfizer.
NCT02791230 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,733 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (124% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02791230, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,733 participants
- Enrollment target
Study Summary
Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy
Primary Outcome
Time to all-cause mortality was calculated from first dose of randomized treatment in parent study (B3461028) to all-cause mortality events. All-cause mortality events included deaths, heart transplants and cardiac mechanical assist devices implantation treated as death. Treated participants from the parent study who discontinued prior to the start of this study were also included in this analysis as planned. Data from participants who dropped out for a liver-only transplantation were handled in
Interventions
- DRUG Tafamidis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,733 participants |
| Start Date | 2016-06-13 |
| Est. Completion | 2023-11-02 |
| Phase | Phase 3 |
What the finished NCT02791230 record still lists
NCT02791230 is an interventional study that assigns participants to a tested intervention. Its 1,733 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (124% higher).
The record links to 0 conditions, and to 1 intervention - of which Tafamidis is the first listed.
NCT02791230 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02791230 about?
NCT02791230 is a clinical study titled "Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy". Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy
What is the current status of trial NCT02791230?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,733 participants. The study started on 2016-06-13. Estimated completion is 2023-11-02.
What interventions are being tested in trial NCT02791230?
The interventions under investigation include: Tafamidis (DRUG).
Who is sponsoring clinical trial NCT02791230?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02791230's enrollment target sits among peer trials
1,733 130th of 2000 higher than 1,871 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06413420 · 1,731 participants
SUNOSI® (Solriamfetol) Pregnancy Registry
- NCT04712656 · 1,739 participants
Effects of CPAP Therapy on Blood Pressure and Heart Rate Variability in Obstructive Sleep Apnea
- NCT06898034 · 1,725 participants
Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
- NCT05934487 · 1,750 participants · NA
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI